The test will greatly expand access to rapid testing and help to ease the pressure on overburdened laboratories.
The new test is highly portable, affordable and gives results in only 15 minutes. The test does not require any equipment to process samples or read the test results and can be administered by health professionals in point of care settings.
Abbott intends to ship tens of millions of BinaxNow tests in September, ramping to 50 m tests a month at the beginning of October.
The BINAXNow test also includes a companion app to allow people to display a digital health pass as proof of a negative test result. If test results are positive, people receive a message to quarantine and talk to their doctor.
The new test is the sixth test Abbott has launched in the US to fight the coronavirus pandemic. These include two molecular laboratory tests, the ID NOW rapid molecular point of care test and two antibody laboratory tests.
ResearchAndMarkets.com is a source for international market research reports and market data.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT